| CLASS | DRUG/TOX | LP7790-1 |
| COMPONENT | Vedolizumab^trough | LP308057-1 |
| PROPERTY | MCnc | LP6827-2 |
| TIME_ASPCT | Pt | LP6960-1 |
| SYSTEM | Ser/Plas | LP7576-4 |
| SCALE_TYP | Qn | LP7753-9 |
| METHOD_TYP | LC/MS/MS | LP95062-3 |
| parent | Vedolizumab | Serum or Plasma | Drug toxicology | LP390600-7 |
| CLASSTYPE | Laboratory class | |
| ORDER_OBS | Both | |
| EXAMPLE_UNITS | ug/mL | |
| EXAMPLE_UCUM_UNITS | ug/mL |
| LONG_COMMON_NAME | en-US | Vedolizumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough |
| LONG_COMMON_NAME | en-US | Vedolizumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough |
| SHORTNAME | en-US | Vedolizumab Trough SerPl LC/MS/MS-mCnc |
| ConsumerName | en-US | Vedolizumab trough, Blood |
| LONG_COMMON_NAME | fr-FR | Védolizumab taux résiduel [Masse/Volume] Sérum/Plasma ; Numérique ; LC/MS/MS |
| LONG_COMMON_NAME | es-MX | Vedolizumab : Suero o Plasma : Punto temporal: Concentración de masa: Cuantitativo: LC / MS / MS |
LOINC Version: 2.77
FHIR